Profectus BioSciences, Inc. (Profectus) announced today that it has executed an Assignment and License Agreement with Wyeth Pharmaceuticals that provides Profectus therapeutic/prophylactic vaccine programs for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papiloma Virus (HPV) and Herpes Simplex Virus (HSV). These programs combine the Wyeth proprietary technologies in the fields of DNA and vectored vaccines used alone and in a prime-boost strategy to prevent and treat infections.
